The value of in vitro studies in a case of neonatal diabetes with a novel Kir6.2‐W68G mutation

Abstract

In infants, especially with novel previously undescribed mutations of the K ATP channel causing neonatal diabetes, in vitro studies can be used to both predict the response to sulphonylurea treatment and support a second trial of glibenclamide at higher than standard doses if the expected response is not observed.